Minerva Neurosciences (NASDAQ:NERV) Posts Earnings Results, Beats Estimates By $0.49 EPS

Minerva Neurosciences (NASDAQ:NERV) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.49, Zacks reports.

Minerva Neurosciences Stock Performance

NASDAQ NERV traded down $0.03 during trading hours on Friday, reaching $1.68. The company’s stock had a trading volume of 5,798 shares, compared to its average volume of 46,747. The company’s 50-day moving average is $2.15 and its two-hundred day moving average is $2.39. Minerva Neurosciences has a fifty-two week low of $1.64 and a fifty-two week high of $3.69. The stock has a market cap of $11.71 million, a PE ratio of -3.81 and a beta of 0.12.

Wall Street Analysts Forecast Growth

NERV has been the subject of a number of research reports. StockNews.com started coverage on shares of Minerva Neurosciences in a research report on Saturday, February 22nd. They set a “sell” rating for the company. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.